| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absence and presence: the potential for art to facilitate improved communication about pain
|
Padfield, Deborah
|
|
|
|
2 |
p. e96-e97
|
artikel
|
| 2 |
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
|
Owen, Roger G
|
|
|
|
2 |
p. e112-e121
|
artikel
|
| 3 |
Acute promyelocytic leukaemia in low-income and middle-income countries: a Brazilian experience
|
Pereira-Martins, Diego A
|
|
|
|
2 |
p. e98-e99
|
artikel
|
| 4 |
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
|
Walker, Irwin
|
|
|
|
2 |
p. e100-e111
|
artikel
|
| 5 |
Advancements in haemophilia A and health equity: is it time to redefine severity?
|
Weyand, Angela C
|
|
|
|
2 |
p. e90-e92
|
artikel
|
| 6 |
Africa's coalition for adequate blood established
|
Makoni, Munyaradzi
|
|
|
|
2 |
p. e106
|
artikel
|
| 7 |
Alisertib: a new option for acute myeloid leukaemia
|
Thomas, Xavier
|
|
|
|
2 |
p. e87-e88
|
artikel
|
| 8 |
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
|
Brunner, Andrew M
|
|
|
|
2 |
p. e122-e133
|
artikel
|
| 9 |
A new, promising, extended half-life rFIX concentrate
|
Morfini, Massimo
|
|
2017
|
|
2 |
p. e59-e60
nvt p.
|
artikel
|
| 10 |
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial
|
Weishaupt, Carsten
|
|
2016
|
|
2 |
p. e72-e79
nvt p.
|
artikel
|
| 11 |
A resurgence of cord blood transplantation?
|
Eapen, Mary
|
|
|
|
2 |
p. e89-e90
|
artikel
|
| 12 |
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
|
|
|
|
|
2 |
p. e117-e128
|
artikel
|
| 13 |
2021 ASH annual meeting
|
del Pozo Martín, Yaiza
|
|
|
|
2 |
p. e92-e93
|
artikel
|
| 14 |
2022 ASH annual meeting
|
Cookson, Emma
|
|
|
|
2 |
p. e87-e88
|
artikel
|
| 15 |
2023 ASH Annual Meeting
|
Cookson, Emma
|
|
|
|
2 |
p. e94-e96
|
artikel
|
| 16 |
A treatise on clinical trials
|
Hilal, Talal
|
|
|
|
2 |
p. e97
|
artikel
|
| 17 |
B-cell receptor stereotypy and chronic lymphocytic leukaemia
|
Michallet, Anne-Sophie
|
|
2014
|
|
2 |
p. e52-e53
nvt p.
|
artikel
|
| 18 |
Bone granulomatous infiltrate associated with mogamulizumab in a patient with mycosis fungoides
|
Carrasquilla-Capilla, Ana
|
|
|
|
2 |
p. e155
|
artikel
|
| 19 |
Brushes with Cancer goes digital
|
Lucas, Catherine
|
|
|
|
2 |
p. e108-e109
|
artikel
|
| 20 |
Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia
|
Buske, Christian
|
|
|
|
2 |
p. e85-e86
|
artikel
|
| 21 |
BTK/PD-1 blockade for treatment of Richter's transformation
|
Tang, Pek Sang
|
|
2019
|
|
2 |
p. e59-e60
|
artikel
|
| 22 |
Catheter-directed thrombolysis: is it worth the risk?
|
Zack, Chad J
|
|
2016
|
|
2 |
p. e54-e55
nvt p.
|
artikel
|
| 23 |
Caution: PET-CT in plasma cell disorders
|
Lad, Deepesh P
|
|
|
|
2 |
p. e95
|
artikel
|
| 24 |
Challenges and new horizons for sickle cell disease
|
The Lancet Haematology,
|
|
2018
|
|
2 |
p. e53
|
artikel
|
| 25 |
Change ahead for cancer drug funding
|
The Lancet Haematology,
|
|
2015
|
|
2 |
p. e47-
1 p.
|
artikel
|
| 26 |
Childhood cancer: the need to invest in the future
|
The Lancet Haematology,
|
|
|
|
2 |
p. e82
|
artikel
|
| 27 |
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
|
Baliakas, Panagiotis
|
|
2014
|
|
2 |
p. e74-e84
nvt p.
|
artikel
|
| 28 |
CLL: when the target of treatment is disease-related symptoms
|
Molica, Stefano
|
|
2017
|
|
2 |
p. e57-e58
nvt p.
|
artikel
|
| 29 |
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
|
Raje, Noopur S
|
|
|
|
2 |
p. e143-e161
|
artikel
|
| 30 |
Correction to Lancet Haematol 2015; 2: e32
|
|
|
2015
|
|
2 |
p. e54-
1 p.
|
artikel
|
| 31 |
Correction to Lancet Haematol 2021; 8: e410–21
|
|
|
|
|
2 |
p. e91
|
artikel
|
| 32 |
Correction to Lancet Haematol 2021; 8: e122–34
|
|
|
|
|
2 |
p. e105
|
artikel
|
| 33 |
Cost considerations in the first-line treatment of advanced Hodgkin lymphoma
|
Perissinotti, Anthony J
|
|
|
|
2 |
p. e91-e93
|
artikel
|
| 34 |
Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study
|
Vijenthira, Abi
|
|
|
|
2 |
p. e146-e156
|
artikel
|
| 35 |
COVID-19 and thrombosis: a continuing story
|
The Lancet Haematology,
|
|
|
|
2 |
p. e95
|
artikel
|
| 36 |
COVID-19 vaccination in haematology services
|
The Lancet Haematology,
|
|
|
|
2 |
p. e95
|
artikel
|
| 37 |
Crowdsourcing biologicals
|
The Lancet Haematology,
|
|
2016
|
|
2 |
p. e53-
1 p.
|
artikel
|
| 38 |
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study
|
Hägele, Pauline
|
|
|
|
2 |
p. e114-e126
|
artikel
|
| 39 |
Discontinuation therapy: the role of emotion and cognition
|
Riva, Silvia
|
|
2016
|
|
2 |
p. e63-
1 p.
|
artikel
|
| 40 |
Don't judge a JAK2 inhibitor by spleen response alone
|
Mascarenhas, John
|
|
2018
|
|
2 |
p. e56-e57
|
artikel
|
| 41 |
Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study
|
Ranque, Brigitte
|
|
2014
|
|
2 |
p. e64-e73
nvt p.
|
artikel
|
| 42 |
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis
|
Conter, Valentino
|
|
2016
|
|
2 |
p. e80-e86
nvt p.
|
artikel
|
| 43 |
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Russo, Domenico
|
|
|
|
2 |
p. e127-e135
|
artikel
|
| 44 |
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
|
Mai, Elias K
|
|
|
|
2 |
p. e101-e113
|
artikel
|
| 45 |
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma
|
Tamura, Hideto
|
|
|
|
2 |
p. e86-e87
|
artikel
|
| 46 |
Eradicating residual chronic myeloid leukaemia: basic research lost in translation
|
Zhao, Helong
|
|
|
|
2 |
p. e101-e104
|
artikel
|
| 47 |
Extended duration of letermovir prophylaxis: how long is long enough?
|
Douglas, Abby P
|
|
|
|
2 |
p. e88-e90
|
artikel
|
| 48 |
First-line hypomethylating agents for patients with high risk chronic myelomonocytic leukaemia
|
Bejanyan, Nelli
|
|
|
|
2 |
p. e99-e101
|
artikel
|
| 49 |
From residency training to professional life: which competencies and skills are most valued by haematologists in Brazil?
|
Barbosa, Ayla Cristina Nobrega
|
|
|
|
2 |
p. e95-e96
|
artikel
|
| 50 |
Genomic imbalances in circulating DNA in Hodgkin's lymphoma
|
Hohaus, Stefan
|
|
2015
|
|
2 |
p. e48-e49
nvt p.
|
artikel
|
| 51 |
Globalisation of clinical trials and ethics of benefit sharing
|
Ravinetto, Raffaella
|
|
2014
|
|
2 |
p. e54-e56
nvt p.
|
artikel
|
| 52 |
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
|
Zhang, Mingming
|
|
|
|
2 |
p. e107-e116
|
artikel
|
| 53 |
GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?
|
Gagelmann, Nico
|
|
|
|
2 |
p. e82-e83
|
artikel
|
| 54 |
GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
|
Bonifazi, Francesca
|
|
2019
|
|
2 |
p. e89-e99
|
artikel
|
| 55 |
Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
|
Cohen, Sandra
|
|
|
|
2 |
p. e134-e145
|
artikel
|
| 56 |
HLA match likelihoods for Indian patients seeking unrelated donor transplantation grafts: a population-based study
|
Maiers, Martin
|
|
2014
|
|
2 |
p. e57-e63
nvt p.
|
artikel
|
| 57 |
Impostors out!
|
Kerep, Ana Zelić
|
|
|
|
2 |
p. e90
|
artikel
|
| 58 |
Improving equity for people living with rare diseases
|
The Lancet Haematology,
|
|
|
|
2 |
p. e85
|
artikel
|
| 59 |
Individualised doses of anti-thymocyte globulin and immune recovery after allogeneic HSCT
|
Baron, Frédéric
|
|
|
|
2 |
p. e84-e86
|
artikel
|
| 60 |
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial
|
Admiraal, Rick
|
|
|
|
2 |
p. e111-e120
|
artikel
|
| 61 |
In-vivo T-cell depletion: burden of morbidity versus survival
|
Eapen, Mary
|
|
2019
|
|
2 |
p. e63-e64
|
artikel
|
| 62 |
Is venous thromboembolism a problem in patients with cancer in palliative care?
|
Sandset, Per Morten
|
|
2019
|
|
2 |
p. e61-e62
|
artikel
|
| 63 |
KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
|
Kaddu-Mulindwa, Dominic
|
|
|
|
2 |
p. e133-e142
|
artikel
|
| 64 |
Lakshmi Nayak: striving to contain the brain's deadliest killers
|
Cavanaugh, Ray
|
|
|
|
2 |
p. e97
|
artikel
|
| 65 |
Lallindra Gooneratne—maintaining treatment flow amid crisis
|
Cavanaugh, Ray
|
|
|
|
2 |
p. e100
|
artikel
|
| 66 |
Letting the sunshine in?
|
The Lancet Haematology,
|
|
2014
|
|
2 |
p. e47-
1 p.
|
artikel
|
| 67 |
Leukaemia cutis and pancreatic and renal enlargement in a neonate
|
Zhou, Lin
|
|
|
|
2 |
p. e156
|
artikel
|
| 68 |
Life prepared me to fight cancer
|
Williams, Tiffany H
|
|
|
|
2 |
p. e107
|
artikel
|
| 69 |
Look! Up in the sky! It's a bird. It's a plane. It's a medical drone!
|
The Lancet Haematology,
|
|
2017
|
|
2 |
p. e56-
1 p.
|
artikel
|
| 70 |
Matchpoint: the game is not over for blast-phase chronic myeloid leukaemia
|
Rousselot, Philippe
|
|
|
|
2 |
p. e86-e87
|
artikel
|
| 71 |
MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
|
Ferreri, Andrés J M
|
|
|
|
2 |
p. e110-e121
|
artikel
|
| 72 |
Melflufen for multiple myeloma: a promise unfulfilled?
|
Kapoor, Prashant
|
|
|
|
2 |
p. e82-e84
|
artikel
|
| 73 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
|
Schjesvold, Fredrik H
|
|
|
|
2 |
p. e98-e110
|
artikel
|
| 74 |
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
|
Harrison, Claire N
|
|
2018
|
|
2 |
p. e73-e81
|
artikel
|
| 75 |
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
|
Morice, Pierre-Marie
|
|
|
|
2 |
p. e122-e134
|
artikel
|
| 76 |
New hope for patients with livedoid vasculopathy
|
Kirsner, Robert S
|
|
2016
|
|
2 |
p. e56-e57
nvt p.
|
artikel
|
| 77 |
Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study
|
Vandenberghe, Peter
|
|
2015
|
|
2 |
p. e55-e65
nvt p.
|
artikel
|
| 78 |
Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia
|
Molica, Stefano
|
|
2019
|
|
2 |
p. e65-e66
|
artikel
|
| 79 |
Of blood and bone: the sotatercept adventure
|
Santini, Valeria
|
|
2018
|
|
2 |
p. e54-e55
|
artikel
|
| 80 |
On the basis of sex: outcomes in myelodysplastic syndromes
|
Hochman, Michael J
|
|
|
|
2 |
p. e83-e85
|
artikel
|
| 81 |
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
|
Pleyer, Lisa
|
|
|
|
2 |
p. e135-e148
|
artikel
|
| 82 |
PARP inhibitors—understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia
|
Tinker, Anna V
|
|
|
|
2 |
p. e97-e99
|
artikel
|
| 83 |
PET in natural killer/T-cell lymphoma: the debate continues
|
Fanti, Stefano
|
|
2015
|
|
2 |
p. e50-e51
nvt p.
|
artikel
|
| 84 |
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
|
Abrisqueta, Pau
|
|
|
|
2 |
p. e136-e146
|
artikel
|
| 85 |
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial
|
Copland, Mhairi
|
|
|
|
2 |
p. e121-e132
|
artikel
|
| 86 |
Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial
|
Haig, Ylva
|
|
2016
|
|
2 |
p. e64-e71
nvt p.
|
artikel
|
| 87 |
Potential for increased stem-cell donor recruitment in India
|
Schmidt, Alexander H
|
|
2014
|
|
2 |
p. e48-e49
nvt p.
|
artikel
|
| 88 |
Preservation of fertility in teenagers and young adults treated for haematological malignancies
|
Yasmin, Ephia
|
|
|
|
2 |
p. e149-e160
|
artikel
|
| 89 |
Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study
|
White, Clare
|
|
2019
|
|
2 |
p. e79-e88
|
artikel
|
| 90 |
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma
|
Procházka, Vít
|
|
2017
|
|
2 |
p. e63-
1 p.
|
artikel
|
| 91 |
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma
|
Adams, Hugo J A
|
|
2017
|
|
2 |
p. e63-e64
nvt p.
|
artikel
|
| 92 |
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply
|
Agostinelli, Claudio
|
|
2017
|
|
2 |
p. e64-e66
nvt p.
|
artikel
|
| 93 |
Production and supply of blood products in Brazil
|
Kirby, Tony
|
|
|
|
2 |
p. e93-e94
|
artikel
|
| 94 |
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
|
Penack, Olaf
|
|
|
|
2 |
p. e157-e167
|
artikel
|
| 95 |
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
|
Penack, Olaf
|
|
|
|
2 |
p. e147-e159
|
artikel
|
| 96 |
Prospective characterisation of non-malignant, paediatric lymphoproliferative disease
|
Torgerson, Troy R
|
|
|
|
2 |
p. e87-e88
|
artikel
|
| 97 |
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials
|
Gupta, Sumit
|
|
|
|
2 |
p. e129-e141
|
artikel
|
| 98 |
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study
|
Fischer, Kathelijn
|
|
2017
|
|
2 |
p. e75-e82
nvt p.
|
artikel
|
| 99 |
Reporting of trials with possible detrimental overall survival: a patient advocate perspective
|
Berger, Katherine
|
|
|
|
2 |
p. e94
|
artikel
|
| 100 |
Retinopathy associated with severe thrombocytopenia
|
Kaspi, Mathilde
|
|
|
|
2 |
p. e166
|
artikel
|
| 101 |
Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health
|
Pasricha, Sant-Rayn
|
|
2018
|
|
2 |
p. e60-e62
|
artikel
|
| 102 |
Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis
|
Kim, Seok Jin
|
|
2015
|
|
2 |
p. e66-e74
nvt p.
|
artikel
|
| 103 |
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice
|
Lonial, Sagar
|
|
|
|
2 |
p. e162-e165
|
artikel
|
| 104 |
Rituximab for adult primary immune thrombocytopenia
|
Frederiksen, Henrik
|
|
2015
|
|
2 |
p. e52-e53
nvt p.
|
artikel
|
| 105 |
Rituximab maintenance is efficacious, but is it useful?
|
O'Brien, Susan
|
|
2018
|
|
2 |
p. e58-e59
|
artikel
|
| 106 |
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study
|
Dartigeas, Caroline
|
|
2018
|
|
2 |
p. e82-e94
|
artikel
|
| 107 |
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
|
Chugh, Shaan
|
|
2015
|
|
2 |
p. e75-e81
nvt p.
|
artikel
|
| 108 |
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial
|
Jain, Preetesh
|
|
2017
|
|
2 |
p. e67-e74
nvt p.
|
artikel
|
| 109 |
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
|
Younes, Anas
|
|
2019
|
|
2 |
p. e67-e78
|
artikel
|
| 110 |
Safety and current status of blood transfusion in China: an update
|
Yu, Xuerong
|
|
2016
|
|
2 |
p. e60-e62
nvt p.
|
artikel
|
| 111 |
Search continues for a CMV vaccine for transplant recipients
|
Boeckh, Michael
|
|
2016
|
|
2 |
p. e58-e59
nvt p.
|
artikel
|
| 112 |
Secondary haematological malignancies
|
The Lancet Haematology,
|
|
|
|
2 |
p. e79
|
artikel
|
| 113 |
Sickle cell disease care in Lebanon: resource-constrained and humanitarian crisis adaptations
|
Yazbek, Soha
|
|
|
|
2 |
p. e91-e92
|
artikel
|
| 114 |
SickleInAfrica
|
Makani, Julie
|
|
|
|
2 |
p. e98-e99
|
artikel
|
| 115 |
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
|
Komrokji, Rami
|
|
2018
|
|
2 |
p. e63-e72
|
artikel
|
| 116 |
Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis
|
Kunutsor, Setor K
|
|
2017
|
|
2 |
p. e83-e93
nvt p.
|
artikel
|
| 117 |
Statins in prevention of venous thromboembolism
|
Undas, Anetta
|
|
2017
|
|
2 |
p. e61-e62
nvt p.
|
artikel
|
| 118 |
Structural racism in clinical research limits its validity and applicability
|
Hamad, Nada
|
|
|
|
2 |
p. e85-e86
|
artikel
|
| 119 |
Susan Kahn—a long-term look at thrombosis
|
Kirby, Tony
|
|
|
|
2 |
p. e89
|
artikel
|
| 120 |
Thank you to our reviewers of 2021
|
The Editors of The Lancet Haematology,
|
|
|
|
2 |
p. e89-e90
|
artikel
|
| 121 |
The best matrix for the brain: advances in secondary CNS lymphoma
|
Dietrich, Jorg
|
|
|
|
2 |
p. e96-e97
|
artikel
|
| 122 |
The demand and supply of blood in India
|
Mammen, Joy John
|
|
|
|
2 |
p. e94
|
artikel
|
| 123 |
The role of conferences in tackling inequalities
|
The Lancet Haematology,
|
|
|
|
2 |
p. e81
|
artikel
|
| 124 |
To begin at the beginning: sickle cell disease in Africa
|
Rees, David C
|
|
2014
|
|
2 |
p. e50-e51
nvt p.
|
artikel
|
| 125 |
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
|
Nastoupil, Loretta J
|
|
2019
|
|
2 |
p. e100-e109
|
artikel
|
| 126 |
To treat, or not to treat: the dilemma for pregnant women
|
The Lancet Haematology,
|
|
2019
|
|
2 |
p. e58
|
artikel
|
| 127 |
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
|
Lew, Thomas E
|
|
|
|
2 |
p. e142-e154
|
artikel
|
| 128 |
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations
|
Tambaro, Francesco Paolo
|
|
|
|
2 |
p. e168-e176
|
artikel
|
| 129 |
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
|
Yong, Kwee
|
|
|
|
2 |
p. e93-e106
|
artikel
|
| 130 |
Upfront autologous transplantation still improving outcomes in patients with multiple myeloma
|
Beksac, Meral
|
|
|
|
2 |
p. e80-e82
|
artikel
|
| 131 |
Using immunogenetics to inform immunotherapy of lymphoid malignancies
|
Vago, Luca
|
|
|
|
2 |
p. e88-e89
|
artikel
|
| 132 |
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond
|
Lacombe, Valentin
|
|
|
|
2 |
p. e160-e167
|
artikel
|
| 133 |
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial
|
Nakamura, Ryotaro
|
|
2016
|
|
2 |
p. e87-e98
nvt p.
|
artikel
|
| 134 |
What's behind chronic graft versus host disease incidence curves?
|
Mussetti, Alberto
|
|
|
|
2 |
p. e83-e84
|
artikel
|
| 135 |
When cancer disguises: small-cell lung cancer masquerading as HIV-associated lymphoma in leukaemic phase
|
Kurosawa, Shuhei
|
|
|
|
2 |
p. e168
|
artikel
|
Tijdschrift beschrijving